Scarica l'app Stockscreener
0.771
1.43%
0.0109
Precedente Chiudi:
$0.7601
Aprire:
$0.75
Volume 24 ore:
212.23K
Relative Volume:
0.60
Capitalizzazione di mercato:
$50.79M
Reddito:
-
Utile/perdita netta:
$-86.08M
Rapporto P/E:
-0.30
EPS:
-2.57
Flusso di cassa netto:
$-72.06M
1 W Prestazione:
-4.81%
1M Prestazione:
-6.04%
6M Prestazione:
-37.32%
1 anno Prestazione:
-47.91%
Intervallo 1D:
$0.75
$0.7813
Intervallo di 1 settimana:
$0.7277
$0.8416
Portata 52W:
$0.66
$2.098
Io Biotech Inc Stock (IOBT) Company Profile
Nome
Io Biotech Inc
Settore
Industria
Telefono
(457) 070-2980
Indirizzo
OLE MAALOES VEH 3, COPENHAGEN
Confronta IOBT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.771 | 50.79M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Io Biotech Inc Borsa (IOBT) Ultime notizie
IO Biotech announces up to €57.5M debt financing from the European Investment Bank - MSN
IO Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank - citybiz
IO Biotech secures €57.5 million EIB loan for cancer vaccines By Investing.com - Investing.com Canada
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Marketscreener.com
IO Biotech Secures €57.5M EIB Loan Facility to Advance Cancer Vaccine Development Pipeline - StockTitan
IO Biotech (NASDAQ:IOBT) Trading Down 1.3%Here's Why - MarketBeat
IO Biotech (NASDAQ:IOBT) Shares Down 1.3% – Here’s What Happened - Defense World
IO Biotech amends bylaws and adjusts fiscal year-end - Investing.com
IO Biotech : Amendments to Bylaws Form 8 K - Marketscreener.com
IO Biotech amends bylaws and adjusts fiscal year-end By Investing.com - Investing.com UK
Cancer Vaccines Pipeline Drugs Analysis Report, 2024: FDA - openPR
(PDF) 756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC) - ResearchGate
Cancer Vaccines Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - Barchart
Cancer Vaccines Market Forecasted to Surge in Coming Years, - openPR
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight - Barchart
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: - openPR
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
IO Biotech stock hits 52-week low at $0.73 amid market challenges - Investing.com UK
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
HC Wainwright Decreases Earnings Estimates for IO Biotech - MarketBeat
Neuronetics (NASDAQ: STIM) Announces Key Financial Updates and FDA Clearance for Adolescent Treatment - Defense World
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Receives $62.50 Average Price Target from Analysts - Defense World
IO Biotech (NASDAQ:IOBT) Given "Buy" Rating at HC Wainwright - MarketBeat
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences - The Manila Times
IO Biotech Reports Advancing Cancer Trials Despite Widening Q3 Losses; Cash Position at $80.2M | IOBT Stock News - StockTitan
IO Biotech Announces Participation in Upcoming Investor Conferences - Marketscreener.com
IO Biotech to Present at Jefferies, Piper Sandler Healthcare Conferences | IOBT Stock News - StockTitan
Asia stocks fall as China stimulus disappoints, deflation persists - Investing.com
IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103 - Marketscreener.com
Promising results for IO Biotech’s cancer vaccine By Investing.com - Investing.com Canada
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study - ForexTV.com
IO Biotech's Cancer Vaccine Shows 81% Disease Control Rate in Lung Cancer Trial | IOBT Stock News - StockTitan
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation - Yahoo Finance
Legend Biotech Chooses Philadelphia for New R&D Center - BioBuzz
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 12.7% - MarketBeat
Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
IO Biotech, Inc. (NASDAQ:IOBT) Shares Sold by Novo Holdings A S - MarketBeat
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable - GlobeNewswire
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, Companies by DelveInsight - Barchart
38,076 Shares in Montauk Renewables, Inc. (NASDAQ:MNTK) Bought by Squarepoint Ops LLC - Defense World
Bank of America Boosts Voya Financial (NYSE:VOYA) Price Target to $88.00 - Defense World
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Norstella introduces a fully integrated data asset for biopharma - European Pharmaceutical Manufacturer
Immuno-Oncology Clinical Trials Market Valuation to Reach $18.1 Billion By 2032 - 대구포스트
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - ForexTV.com
VerImmune Secures $4.5 Million to Drive Biotech Innovation - BioBuzz
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - The Manila Times
ARHT Media Inc. Announces Filing for Bankruptcy - The Manila Times
Io Biotech Inc Azioni (IOBT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Io Biotech Inc Azioni (IOBT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10% Owner |
Jul 25 '24 |
Sale |
1.33 |
51,522 |
68,339 |
4,377,927 |
| Novo Holdings A/S | 10% Owner |
Jul 26 '24 |
Sale |
1.31 |
23,478 |
30,787 |
4,354,449 |
| Novo Holdings A/S | 10% Owner |
May 10 '24 |
Sale |
1.22 |
658,809 |
802,495 |
4,429,449 |
| Novo Holdings A/S | 10% Owner |
Feb 09 '24 |
Sale |
1.50 |
658,809 |
988,411 |
5,088,258 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):